

# Zhengxin Cai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3355961/publications.pdf>

Version: 2024-02-01

48  
papers

1,156  
citations

331670

21  
h-index

414414

32  
g-index

58  
all docs

58  
docs citations

58  
times ranked

1579  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 224-230.	1.0	90
2	PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. <i>Neuroscience Letters</i> , 2019, 691, 44-50.	2.1	85
3	Synthesis and <i>in Vivo</i> Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1544-1554.	3.5	70
4	First-in-Human Evaluation of <sup>18</sup> F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. <i>Journal of Nuclear Medicine</i> , 2021, 62, 561-567.	5.0	60
5	In Vivo Synaptic Density Imaging with <sup>11</sup> C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1780-1786.	5.0	57
6	New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides. <i>Chemical Communications</i> , 2014, 50, 43-45.	4.1	46
7	PET Imaging for Early Detection of Alzheimer's Disease. <i>PET Clinics</i> , 2017, 12, 329-350.	3.0	44
8	Approaches to PET Imaging of Glioblastoma. <i>Molecules</i> , 2020, 25, 568.	3.8	42
9	Comparison of Conjugation Strategies of Cross-Bridged Macrocyclic Chelators with Cetuximab for Copper-64 Radiolabeling and PET Imaging of EGFR in Colorectal Tumor-Bearing Mice. <i>Molecular Pharmaceutics</i> , 2014, 11, 3980-3987.	4.6	38
10	Synthesis and in vivo evaluation of [ <sup>18</sup> F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1952-1965.	6.4	38
11	Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	38
12	Studies Directed toward the Synthesis of Hamigeran B: A Catalytic Oxidative Cyclization. <i>Organic Letters</i> , 2010, 12, 5668-5670.	4.6	35
13	C <sup>12</sup> H Activation in $\alpha$ -Alkenyl Sulfoximines: An Endo 1,5-Hydrogen Migration. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 7016-7019.	13.8	35
14	<sup>64</sup> Cu-Labeled Somatostatin Analogues Conjugated with Cross-Bridged Phosphonate-Based Chelators via Strain-Promoted Click Chemistry for PET Imaging: In silico through in Vivo Studies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6019-6029.	6.4	35
15	Synthesis and Preclinical Evaluation of an <sup>18</sup> F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [ <sup>18</sup> F]SynVesT-2. <i>ACS Chemical Neuroscience</i> , 2020, 11, 592-603.	3.5	34
16	Total Synthesis of the Terpenoid Buddledone A: 11-Membered Ring-Closing Metathesis. <i>Organic Letters</i> , 2012, 14, 1661-1663.	4.6	28
17	Novel <sup>18</sup> F-Labeled $\mu$ -Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of <sup>18</sup> F-LY2459989 in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2018, 59, 140-146.	5.0	28
18	PET Imaging Evaluation of Four <sup>1</sup> Radiotracers in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2017, 58, 982-988.	5.0	24

#	ARTICLE	IF	CITATIONS
19	Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. <i>Journal of Neuroimaging</i> , 2020, 30, 251-266.	2.0	24
20	Benzothiazines in Synthesis. A Formal Total Synthesis of Pseudopteroxazole. <i>Journal of Organic Chemistry</i> , 2009, 74, 5559-5561.	3.2	23
21	Fluorine-18-Labeled Antagonist for PET Imaging of Kappa Opioid Receptors. <i>ACS Chemical Neuroscience</i> , 2017, 8, 12-16.	3.5	23
22	Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A <sup>+</sup> Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity. <i>Molecular Imaging and Biology</i> , 2020, 22, 832-841.	2.6	23
23	Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1327-1338.	6.4	23
24	Small Molecule Natural Products and Alzheimer's Disease. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 187-204.	2.1	23
25	Cu(II)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides. <i>Dalton Transactions</i> , 2015, 44, 3945-3948.	3.3	20
26	Quantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging. <i>Molecular Imaging and Biology</i> , 2021, 23, 372-381.	2.6	20
27	Optimized and Automated Radiosynthesis of [18F]DHMT for Translational Imaging of Reactive Oxygen Species with Positron Emission Tomography. <i>Molecules</i> , 2016, 21, 1696.	3.8	18
28	A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1482-1496.	6.4	16
29	A Novel <sup>18</sup> F-Labeled Radioligand for Positron Emission Tomography Imaging of 11 $\beta$ -Hydroxysteroid Dehydrogenase (11 $\beta$ -HSD1): Synthesis and Preliminary Evaluation in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2450-2458.	3.5	12
30	First in-human PET study and kinetic evaluation of [ <sup>18</sup> F]AS2471907 for imaging 11 $\beta$ -hydroxysteroid dehydrogenase type 1. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 695-704.	4.3	10
31	Positron Emission Tomography Imaging Evaluation of a Novel 18F-Labeled Sigma-1 Receptor Radioligand in Cynomolgus Monkeys. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1673-1681.	3.5	10
32	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
33	Carbon <sup>+</sup> Carbon Anion Relay Chemistry: Facile Generation of Substituted Allyllithium Species. <i>European Journal of Organic Chemistry</i> , 2011, 2011, 5255-5260.	2.4	9
34	<sup>64</sup> Cu-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 74-83.	1.0	9
35	Bridging from Brain to Tumor Imaging: (S)-(-)- and (R)-(+)-[18F]Fluspidine for Investigation of Sigma-1 Receptors in Tumor-Bearing Mice. <i>Molecules</i> , 2018, 23, 702.	3.8	9
36	Visualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging. <i>Journal of General Virology</i> , 2015, 96, 3131-3142.	2.9	8

#	ARTICLE	IF	CITATIONS
37	Synthesis and preliminary evaluation of an 18 F-labeled oleic acid analog for PET imaging of fatty acid uptake and metabolism. <i>Nuclear Medicine and Biology</i> , 2016, 43, 108-115.	0.6	7
38	Feasibility study of PET dynamic imaging of [18F]DHMT for quantification of reactive oxygen species in the myocardium of large animals. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 216-225.	2.1	5
39	PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging. <i>Frontiers in Neuroscience</i> , 2022, 16, 787404.	2.8	5
40	PET Imaging in Animal Models of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, .	2.8	4
41	Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET. <i>EJNMMI Physics</i> , 2022, 9, 32.	2.7	3
42	Benzothiazines in organic synthesis: formation of a cyclopropane via neighboring group participation. <i>Tetrahedron Letters</i> , 2013, 54, 814-816.	1.4	2
43	Further Investigation of Synaptic Vesicle Protein 2A (SV2A) Ligands Designed for Positron Emission Tomography and Single-Photon Emission Computed Tomography Imaging: Synthesis and Structure-Activity Relationship of Substituted Pivridinylmethyl-4-(3,5-difluorophenyl)pyrrolidin-2-ones. <i>ACS Omega</i> , 2021, 6, 27676-27683.	3.5	2
44	The Therapeutic Potential of Purinergic Receptors in Alzheimer's Disease and Promising Therapeutic Modulators. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1288-1302.	2.4	1
45	ErgÄnzung: C13;H Activation in S-Alkenyl Sulfoximines: An Endo 1,5-Hydrogen Migration. <i>Angewandte Chemie</i> , 2012, 124, 10585-10585.	2.0	0
46	Addition: C13;H Activation in S-Alkenyl Sulfoximines: An Endo 1,5-Hydrogen Migration. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 10437-10437.	13.8	0
47	Innentitelbild: C13;H Activation in S-Alkenyl Sulfoximines: An Endo 1,5-Hydrogen Migration (Angew.) Tj ETQq1 1 0.784314 rgBT /Overbo	2.0	0
48	P-B3â€fVisualize and quantify simian immunodeficiency virus-infected cells in vivo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 83.	2.1	0